Bladder Cancer Accelerated Approvals: Merck, Genentech PD-1/L1 Inhibitors Prevail At US FDA Panel, But For Different Reasons

 
• By Sarah Karlin-Smith
two different, diverging roads
Keytruda and Tecentriq took different paths to positive ODAC votes • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers